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Approximately 50% of early-stage non-small cell lung cancer (NSCLC) patients that 35 
undergo surgery with curative intent will relapse within 5 years1,2. Detection of 36 
circulating tumour cells (CTCs) at the time of surgery may represent a tool to identify 37 
patients at higher risk of recurrence where more frequent monitoring is advised. 38 
Here, we asked whether CellSearch detected pulmonary venous CTCs (PV-CTCs) 39 
at surgical resection of early stage NSCLC represent subclones responsible for 40 
subsequent disease relapse. PV-CTCs were detected in 48% of 100 patients 41 
enrolled into the TRACERx study3 and were associated with lung cancer specific 42 
relapse, and remained an independent predictor of relapse in multivariate analysis 43 
adjusted for tumour stage. In a case study, genomic profiling of single PV-CTCs 44 
collected at surgery revealed a higher mutation overlap with a metastasis detected 45 
10 months later (91%) compared to the primary tumour (79%), suggesting that early 46 
disseminating PV-CTCs were responsible for disease relapse. Together, PV-CTC 47 
enumeration and genomic profiling highlight the potential of PV-CTCs as early 48 
predictors of NSCLC recurrence after surgery. However, limited sensitivity of PV-49 
CTCs to predict relapse suggests further studies using a larger, independent cohort 50 
are warranted to confirm and better define this potential clinical utility of PV-CTCs in 51 
early stage NSCLC.  52 
 53 
Lung cancer is the leading cause of cancer related deaths worldwide with a 5 year 54 
relative survival rate of 4% in the metastatic setting4. NSCLC is the most common 55 
form of lung cancer. Patients presenting with early-stage NSCLC may undergo 56 
surgery with or without adjuvant chemotherapy and/or adjuvant radiotherapy in an 57 
attempt to achieve cure. However, disease recurrence following surgery is common, 58 
with 5-year relapse rates ranging from ~20% in patients with stage I disease to ~50% 59 
in those with stage III disease1,2. 60 
 3 
Strategies to understand the biology of early dissemination and to identify patients at 61 
high risk of relapse may inform novel therapeutic approaches for adjuvant treatment 62 
to improve cure rates. CTCs are the assumed ‘foundations of metastasis’5, though 63 
this has not been formally proven in NSCLC. CTCs enriched from breast cancer, 64 
melanoma, NSCLC and small cell lung cancer (SCLC) patients’ peripheral blood can 65 
form tumours in immune compromised mice confirming their tumorigenic potential6-9. 66 
CTC number, measured using the CellSearch® platform, is a Food and Drug 67 
Administration (FDA) approved prognostic test in breast, colorectal and prostate 68 
cancers and is also prognostic in NSCLC10. Although peripheral blood CTCs (using 69 
CellSearch that captures only cells expressing EpCAM and Cytokeratin) are rare in 70 
early stage NSCLC patients, we previously demonstrated in a pilot study that 71 
CellSearch CTCs obtained from the draining pulmonary vein of the cancer-affected 72 
lung (PV-CTCs) are more frequent and we observed a trend towards worse disease-73 
free survival (DFS) and overall survival (OS)11. To determine whether our preliminary 74 
findings that PV-CTCs at resection are associated with relapse holds in a larger 75 
patient cohort, we enumerated PV-CTCs from 100 NSCLC patients enrolled onto the 76 
TRACERx study12.  77 
 78 
In our current cohort of 100 TRACERx patients (46% stage I, 34% stage II and 20% 79 
stage III; median follow-up 993 days), (Figure 1a, Table 1 and Supplementary Table 80 
1), 48% (48/100) harboured at least 1 PV-CTC per/7.5mL blood (mean ± SD, 42.2 ± 81 
127.3, median 0, range 0-896) (Figure 1b). PV-CTC count was not significantly 82 
associated with clinicopathological factors such as age, gender, pathological stage, 83 
smoking status and treatment received (Figure 1c and Supplementary Table 2). In 84 
contrast to circulating tumour DNA (ctDNA)13, PV-CTC count was not significantly 85 
different between adenocarcinoma (LUAD) and non-LUAD (p=0.554, t-test) 86 
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suggesting that factors that control release of ctDNA and the dissemination of intact 87 
CTCs are distinct.  88 
In our previous pilot study of 30 patients11, there was an association between the 89 
PV-CTC 'high' count (18 PV-CTCs/7.5ml blood) and DFS (p=0.055). When we 90 
applied this cutpoint in the TRACERx cohort there was a significant association with 91 
poorer DFS (p=0.019 log-rank, HR=2.28, Figure 2a) and this remained an 92 
independent predictor in multivariate analysis when adjusted for tumour stage 93 
(p=0.021, HR=2.4, 95% CI 1.14-5.2, Figure 2b). However, the performance of this 94 
cutpoint in predicting DFS, defined by time-dependent receiver operating 95 
characteristic (tdROC) curves, revealed limited sensitivity (sensitivity = 31.7%, 96 
specificity = 84.9%). We therefore conducted futher exploratory analysis to refine the 97 
‘PV-CTC high’ cutpoint to predict lung cancer specific relapse events and investigate 98 
the biological relevance of PV-CTCs in NSCLC metastasis. Briefly, of the 37 99 
recorded DFS events in the TRACERx cohort, 22 were due to lung cancer specific 100 
relapse. The remaining events occurred either without evidence of lung cancer 101 
relapse before death (n=9, Supplementary Table 3) due to a second non-lung 102 
primary cancer (n=4, confirmed by histology, imaging and clinical discussion, 103 
Supplementary Table 3) or lacked sufficient clinical information to determine cause 104 
(n=2, Supplementary Table 3). tdROC curves showed that the sensitivity and 105 
specificity in predicting lung cancer specific relapse at two years was optimal when a 106 
75th quantile cutpoint was applied (≥7 PV-CTCs/7.5ml blood, Extended Data Fig.1a). 107 
A ‘PV-CTC high’ status of ≥7 PV-CTCs/7.5ml blood showed significant association 108 
with lung cancer relapse in Kaplan-Meier analysis (p=0.009 log-rank, HR=2.78, 109 
Extended Data Fig.1b) and remained an independent predictor in multivariate 110 
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analysis when adjusted for tumour stage (p=0.027, HR = 2.6, 95% CI 1.1-6.2, 111 
Extended Data Fig.1c).  112 
Analysis of PV-CTCs as a continuous variable showed that each doubling of PV-113 
CTC count was a significant prognostic factor for DFS when modelled as a sole 114 
covariate (p=0.035, HR=1.113) and when modelled with other significant prognostic 115 
factors (p=0.040, HR=1.116, 95% CI 1.005-1.239, Wald test two-sided, 116 
Supplementary Table 4). Each doubling of PV-CTC count was also significantly 117 
associated with lung cancer specific relapse in both uni-variate (p=0.029, HR=1.148) 118 
and multi-variate analysis (p=0.024, HR=1.170, 95% CI 1.021-1.341, Wald test two-119 
sided, Supplementary Table 5). We also noted a significant association between PV-120 
CTCs as a continuous variable and intracranial disease present at clinical relapse 121 
(p=0.028, t-test two-sided, Supplementary Table 2). 122 
Collectively, these data raise the possibility that patients with a ‘high’ CellSearch PV-123 
CTC count at resection may benefit from increased minimal residual disease (MRD) 124 
monitoring post-surgery. We have shown that increasing PV-CTC count as a 125 
continuous variable is associated with poor prognosis. To use PV-CTCs in a clinical 126 
setting, a pre-defined cutpoint will be required to prospectively stratify patients. 127 
Although the previously defined cutpoint of ≥18 PV-CTCs/7.5ml blood11 was verified 128 
here and the further exploratory analysis of a ≥7 PV-CTC/7.5ml blood increased the 129 
performance of PV-CTCs in predicting lung cancer specific relapse, sensitivity 130 
remained modest (45.2% for ≥7 PV-CTCs/7.5ml blood vs 32.8% for ≥18 PV-131 
CTCs/7.5ml blood, Extended Data Fig.2a) and further studies are clearly required 132 
before clinical utility can be evaluated.   133 
 134 
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We next sought to assess the degree of genomic similarity between early-135 
disseminated PV-CTCs and metastatic disease by comparing  the primary tumour, 136 
the PV-CTCs and subsequent metastatic disease from the same patient. Single PV-137 
CTCs and white blood cell (WBCs) controls were successfully isolated from 14 138 
patients (Extended Data Fig. 2a and online methods). Of these 14 patients, five 139 
experienced a lung cancer specific relapse event (Extended Data Fig.2b); with an 140 
evaluable metastatic tissue biopsy available for one patient (CRUK0242). This 74-141 
year old male was diagnosed with stage IIIA, invasive adenocarcinoma in the right 142 
lung and underwent tumour resection, at which point 28 PV-CTCs were detected. 143 
The patient received adjuvant chemotherapy and radiotherapy and at 10 months 144 
post-surgery, positron-emission tomography (PET) identified relapse involving the 145 
right pleura. At this time a biopsy from the right pleural lesion was sequenced and 146 
peripheral blood samples collected for circulating free DNA (cfDNA) analysis. After 147 
receiving palliative chemotherapy and radiotherapy, the patient progressed and died 148 
the following year (Figure 3a). In this case study, three spatially-separated primary 149 
tumour regions, PV-CTCs, cfDNA isolated from pulmonary and peripheral veins at 150 
resection and again from the periphery at disease relapse, and the pleural 151 
metastasis were genetically profiled and compared.  152 
From the 28 PV-CTCs detected by CellSearch, we successfully isolated and 153 
amplified six single PV-CTCs (Extended Data Fig. 2c). Low-pass whole genome 154 
sequencing was performed which revealed that 3/6 PV-CTCs harboured copy 155 
number alterations (CNA) that matched the primary tumour. The remaining cells, 156 
although phenotypically CTC candidates by CellSearch criteria, showed flat copy 157 
number profiles as observed in WBC controls (Figure 3b, Extended Data Fig. 2d). 158 
We have termed these cells 'circulating epithelial cells' (CECs) and propose these 159 
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are likely to be normal epithelial cells that enter the blood along with PV-CTCs; 160 
similar cells have recently been described in non-cancer patients14. In order to 161 
identify somatic mutations present in the PV-CTCs, we performed whole exome 162 
sequencing (WES) followed by targeted deep sequencing of the 3 PV-CTCs, 3 CECs 163 
and 2 WBC controls. This identified 198 mutations (single nucleotide variants, SNVs) 164 
in the PV-CTCs and none in the CECs (Figure 3c). After accounting for technical 165 
drop-out due to the single cell sequencing approach (loci drop-out = 102/441 in 166 
tumour, 81/342 in metastasis)15 (Supplementary Table 6 and 7, methods online), 167 
46% (157/339) of all primary tumour mutations were also detected in PV-CTCs 168 
(Figure 3c and Extended Data Fig. 3a). Along with the CNA data this confirms the 169 
tumour origin of the PV-CTCs, but the presence of PV-CTC mutations not detected 170 
in the primary tumour suggests these cells may represent a minor subclone of the 171 
tumour. Although a resolvable tumour specific CNA pattern was not observed in the 172 
metastasis (Figure 3b), due to low tumour content, WES and targeted deep 173 
sequencing revealed 91% of the PV-CTC mutations were seen in the metastasis 174 
(181/198), which is a higher mutational overlap than between the PV-CTCs and 175 
primary tumour (157/198, 79%) (Figure 3c and Extended Data Fig.3a). In addition, 176 
96.8% (120/124) of the primary tumour mutations that were not detected in the 177 
metastasis were also not detected in the PV-CTCs (Figure 3c). Strikingly, of the 41 178 
PV-CTC private mutations that were not detected in the primary tumour, 28 (68.3%) 179 
were identified in the relapse biopsy WES (Figure 3c and Extended Data Fig.3a) 180 
suggesting that the PV-CTCs present in the patient’s blood at surgery share a 181 
common progenitor with the metastasis that was detected 10 months later. The 182 
evolutionary origin of the PV-CTCs and metastasis was confirmed by phylogenetic 183 
analysis that revealed both PV-CTCs and metastasis are part of the same specific 184 
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branch, which is distinct from all other subclones of the primary tumour (Figure 3d). 185 
The identification of PV-CTC specific mutations that are undetectable by bulk tumour 186 
analysis, yet are present in the relapse samples, strongly suggests that the PV-CTCs 187 
belong to a minor tumour subclone which is responsible for eventual relapse.  188 
Examination of the mutations shared between PV-CTCs and the metastatic biopsy 189 
yet absent from the primary tumour has the potential to give insight into the 190 
mechanisms of metastasis. In this patient, the 28 PV-CTC/metastatic associated 191 
mutations not detected in the primary tumour included a putative inactivating driver 192 
mutation in the tumour suppressor gene LZTS1 (p.Pro104His) (Supplementray Table 193 
8) which has been shown to inhibit tumour migration and whose lower expression 194 
has been linked to poor overall survival in NSCLC16.  195 
Finally, to address the question whether the 13 private PV-CTC mutations not initially 196 
detected in the primary tumour or relapse biopsy, were in fact present at low 197 
frequency, additional targeted deep-sequencing of the tumour and metastasis was 198 
performed. All 13 mutations were present in either the primary tumour (5/13), the 199 
metastasis (12/13) and/or relapse cfDNA (7/13) (Figure 3e, Extended Data Fig.3b 200 
and Extended Data Fig.4). Interestingly, even using targeted deep-sequencing none 201 
of the 520 pre-identified mutations were detected in either baseline pulmonary or 202 
peripheral blood cfDNA samples (Extended Data Fig.4), highlighting the unique 203 
aspect of molecular analysis of PV-CTCs at resection. 204 
Previous studies have shown a genetic link between CTCs, primary tumour and 205 
metastasis with clonal and subclonal mutations detected in CTCs in both colorectal 206 
and prostate cancer17,18. However, these studies were performed in metastatic 207 
patients and to our knowledge, this case report is the first to show that CTCs at 208 
surgery are phylogenetically linked to subsequent metastatic disease. This is 209 
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exemplified by the larger mutational overlap between the PV-CTCs and the 210 
metastatic tumour that arose 10 months post PV-CTC isolation, than between the 211 
PV-CTCs and primary tumour which were collected at the same time in our case 212 
study. Comprehensive molecular analysis of early disseminating PV-CTCs also 213 
raises the opportunity to identify putative mechanisms of metastatic spread from the 214 
primary tumour prior to establishment of recurrent disease. 215 
 216 
In early-stage NSCLC disease recurrence post-surgery occurs frequently and in this 217 
scenario survival is dismal; therefore, strategies that enable the identification of 218 
patients at higher risk of recurrence are an unmet medical need. We show here PV-219 
CTC count (using the CellSearch platform) is associated with DFS and lung cancer 220 
specific survival in the TRACERx cohort, reinforcing the biological importance of PV-221 
CTCs as founders of NSCLC metastasis. However, the clinical strength of a PV-CTC 222 
count to predict lung cancer specific relapse is modest and requires further validation 223 
in an independent and prospective patient cohort.  Reasons underpinning the 224 
modest predictive strength of PV-CTC counts for NSCLC specific relapse could 225 
include the co-existence of CECs and bonafide epithelial CTCs as seen in the blood 226 
sample of the case study. This mixed population of EpCAM positive cells could  227 
confound the true PV-CTC count and the inability of CellSearch to detect 228 
mesenchymal CTCs further reduce the sensitivity of this approach. Additional 229 
detailed investigations are warranted to differentiate between epithelial  and 230 
mesenchymal CTCs and CECs and to incorporate this greater understanding into 231 
NSCLC relapse prediction models. This study highlights the benefit of combining PV-232 
CTC, tumour and cfDNA analysis to unearth new biological insights into the process 233 
of NSCLC metastasis.   234 
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Figure Legends 337 
Fig. 1: PV-CTC detection in early NSCLC. a, TRACERx consort diagram. 149 338 
patients consented for pulmonary vein blood sampling between June 2014 and 339 
March 2017. 27 samples were excluded because of failures in CellSearch® 340 
enrichment and enumeration. 22 patients were defined ineligible post-surgery and 341 
the remaining 100 patients constituted the final cohort for PV-CTC 342 
enumeration. b, Distribution of the number of PV-CTCs enumerated by CellSearch® 343 
from 100 patients with early NSCLC. LUAD (blue circle) and non-LUAD (red circle)  344 
patients are indicated. c, Heat map showing clinicopathological and PV-CTC 345 
detection data; Patients are stratified according to PV-CTC detection. Histological 346 
disease type is indicated by coloured bar above the heatmap.  347 
 348 
Fig.2: PV-CTCs as independent predictors of disease-free survival. a, Kaplan–349 
Meier curves showing disease-free survival (DFS) of 100 patients stratified as PV-350 
CTC high or low based on the previously published threshold from our pilot study 351 
(18 PV-CTCs/7.5ml blood)11. The number of patients at risk for every time point is 352 
indicated below the time point and colour coded according to the high or low groups. 353 
P value, HR and relative 95% confidence intervals (CI) (two-sided log-rank test) are 354 
indicated. b, Forest plot showing the results of multivariable regression analysis for 355 
PV-CTC high or low patients (18 PV-CTCs/7.5ml blood). The x-axis represents the 356 
hazard ratio with the reference line (dashed) and significance is calculated using a 357 
Cox proportional hazards model. The estimated hazard ratios and their 95% CI are 358 
presented as error bars. The log-rank test used was two-sided. 359 
 360 
Fig.3: Mutations present in the relapse tumour are detected 10 months earlier 361 
in PV-CTCs and not in the primary tumour. a, Patient timeline from diagnosis to 362 
death (FU=follow up; PET=positron emission tomography; MR=magnetic 363 
resonance). b, Heat map showing the comparison between CNA detected in PV-364 
CTCs or circulating epithelial cells (CECs), in primary tumour regions (R1-3), in 365 
relapse tumour (Met) and in a WBC control. Regions of loss are coloured blue, 366 
regions of gain are coloured red. Chromosomes are indicated at the top of the figure. 367 
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c, Heat map showing the comparison of SNVs detected in PV-CTCs, primary tumour 368 
regions and the metastasis. Mutations are ordered according to their clonality as 369 
established by primary tumour analysis. Green dashed boxes indicate mutations that 370 
are seen in the primary tumour, but not metastasis or PV-CTCs. Blue dashed box 371 
indicates the overlap between mutations considered metastatic private by primary 372 
tumour analysis and PV-CTCs. No mutations were found in the three CECs and two 373 
WBCs. d, Evolutionary tree encompassing tumour and PV-CTCs: the relationships 374 
between identified subclones is depicted, with size of circle reflecting the number of 375 
mutations in each subclone relative to largest. Length of lines connecting tumor 376 
subclones does not carry information. The beehive plots indicate the subclonal 377 
architecture of each tumour region, with 100 representative cells shown for each 378 
region and the nested colours corresponding to the ancestry of each cell. e, Heat 379 
map showing PV-CTC private mutations that are detected in primary tumour, 380 
metastasis and cfDNA following targeted deep sequencing. 381 
 382 
Extended Data Fig.1: a, Time-dependent receiver operating characteristic (ROC) 383 
curves showing true positive and false positive rates for the 65th , 75th, 85th PV-CTC 384 
quantiles (3, 7 and 39 PV-CTCs/7.5ml blood respectively) alongside the 385 
previously published threshold from our pilot study (18 PV-CTCs/7.5ml blood)11. All 386 
predictions were made at 720 days. Sensitivity and specificity of each category is 387 
shown along with area under ROC curve (AUROC) value. b, Kaplan–Meier curve 388 
showing lung cancer specific relapse free survival for 98 patients stratified as PV-389 
CTC high or low according to the 75th quantile (7 PV-CTCs/7.5ml blood). The 390 
number of patients at risk for every time point is indicated below the time point and 391 
colour coded according to the high or low groups. P value, HR and relative 95% 392 
confidence intervals (CI) (two-sided log-rank test) are indicated. c, Forest plot 393 
showing the results of multivariable regression analysis for PV-CTC high or low 394 
patients (7 PV-CTCs/7.5ml blood). The x-axis represents the hazard ratio with the 395 
reference line (dashed) and significance is calculated using a Cox proportional 396 
hazards model.   397 
 398 
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Extended Data Fig.2: a, Consort diagram describing samples used for downstream 399 
analysis. Only patients with ≥5 PV-CTCs (29) were processed through single cell 400 
isolation (DEPArray™). Single cells were not isolated from 6 out of the 29 samples 401 
due to failures during sample loading into the DEPArray™ machine. From the 402 
remaining 23 samples, 7 patients whose single CTCs isolated did not meet 403 
morphology criteria (see methods) were excluded. 16 samples were processed for 404 
whole genome amplification (WGA) and 2 patients whose CTCs did not show good 405 
quality genomic integrity index in QC post-WGA were removed (see methods). b, 406 
Table showing cases of relapse among the patients with single PV-CTCs isolated. c, 407 
Agarose gel showing results of a QC–PCR assay used to determine the genome 408 
integrity of each sample. 0–4 bands determine the overall DNA integrity of each 409 
sample. DEPArray images of corresponding PV-CTC (cytokeratin (CK)+ stained 410 
green, CD45+ stained blue, DAPI+ stained purple) are shown above. d, Examples of 411 
copy number profiles detected in single PV-CTCs, CECs and WBC control. Blue and 412 
red indicate regions of copy number loss and gain respectively. 413 
  414 
Extended Data Fig.3: a, Venn diagram showing the overlap of somatic mutations 415 
detected between single PV-CTCs, primary and metastatic tumour. b, Venn diagram 416 
showing the overlap of somatic mutations detected between single PV-CTCs, 417 
metastatic tumour and cfDNA isolated at the time of relapse. 418 
  419 
Extended Data Fig.4: Heat map showing the comparison of SNVs detected in 420 
primary tumour regions, metastasis, PV-CTCs, CECs, WBCs, and cfDNA samples 421 
(cfDNA pre-surgery was isolated from peripheral blood, cfDNA surgery was isolated 422 
from the pulmonary vein and cfDNA relapse was isolated at the time of relapse). 423 
Mutations are ordered according to their clonality established by primary tumour 424 
analysis. 425 
 426 
 427 
  428 
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Table 1- Baseline characteristics of 100 patients and presence of 
PV-CTCs  
Characteristics 
PV-CTC positive,  
n (%)  
PV-CTC negative,  
n (%) 
Age, in years     
Average age  68 67 
Range 39-85 48-82 
      
Gender     
Male (n=61) 28 (46%) 33 (54%) 
Female (n=39) 20 (51%) 19 (49%) 
      
Tumour Histology      
Adenocarcinoma 
(n=59) 28 (47%) 
31 (53%) 
Non-adenocarcinoma 
(n=43)  20 (47%) 
23 (53%) 
      
Pathological Stage     
I (n=47) 22 (47%)  25 (53%) 
II (n=34) 15 (44%)  19 (56%) 
III (n=19) 11 (58%)  8 (42%) 
      
Smoking Status     
Current smokers 
(n=14) 7 (50%)  7 (50%) 
ex smokers (n=78) 38 (49%)  40 (51%) 
never smokers (n=8) 3 (37%) 5 (63%) 
  429 
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Online Methods  430 
Patients and pathology review  431 
The cohort of 100 patients evaluated here for PV-CTC detection within this study 432 
comprises patients analysed by the lung TRACERx study 433 
(https://clinicaltrials.gov/ct2/show/NCT01888601).  Patient eligibility and exclusion 434 
criteria for TRACERx enrolment is described in Jamal-Hanjani et al12 but briefly 435 
patients had given their informed written consent to participate in the study, were at 436 
least 18 years of age, had received a diagnosis of NSCLC in stages IA through IIIA 437 
and not received previous systemic therapy. The study has received a favourable 438 
opinion from the NRES Committee London – Camden & Islington Research Ethics 439 
Committee. The clinical data used in this study was derived from the “February 2019 440 
TRACERx data release”. The NSCLC cohort in this study consisted of lung 441 
adenocarcinoma (LUAD) (59%) and remaining 41% of non-adenocarcinoma 442 
histology (Extended Data Fig. 1b and Supplementary  Tables 1 and 2). The median 443 
age of patient was 68 and the population consisted of 61 males and 39 females 444 
(Table 1).   445 
Digital images of diagnostic tumour sections from all cases were reviewed in detail 446 
centrally by at least one pathologist, and in cases of uncertainty, by two. Histological 447 
subtype and mitotic rate (number of visible mitoses per high-power field) were 448 
evaluated on digital images from scanned diagnostic slides blinded to the PV-CTC 449 
detection status of the patient in question. 450 
 451 
Statistical analysis  452 
All statistical tests were 2-sided unless otherwise stated. The association of PV-CTC 453 
count with individual clinical characteristics, including gender, stage, histology, 454 
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smoking status, chemotherapy received, sites of relapse were evaluated using 455 
ANOVA, while age and mitotic rate were evaluated using Pearson’s correlation. PV-456 
CTC count was log2 transformed in all analysis. 457 
 458 
Cox proportional hazard regression analysis 459 
The association between PV-CTC count and patient survival (DFS or lung cancer 460 
specific relapse) was assessed by including it as a sole covariate in a Cox 461 
proportional hazards model. Assumption of proportionality was verified based on 462 
Schoenfeld residuals19. A plot of the Martingale residuals was examined for evidence 463 
of nonlinearity20. The same uni-variate analysis was carried out on each clinical 464 
characteristic. Significant covariates in the uni-variate analysis were selected for 465 
subsequent multi-variate analysis, where a backward stepwise method was applied 466 
to investigate the impact of PV-CTC count on survival with other significant clinical 467 
characteristics under control. 468 
Time-dependent receiver operating characteristics (tdROC) curves were applied to 469 
evaluate the performance of predicting lung cancer specific relapse using PV-CTC 470 
counts stratified by the 65th, 75th, 85th quantiles and the previously published 471 
threshold from our pilot study11 (18 PV-CTCs/7.5ml blood) within 720 days post-472 
surgery. This analysis showed the upper quartile (75th quantile) had the highest 473 
AUROC (0.58, Extended Data Fig.1a). The diagnostic odds ratio (DOR) was also 474 
calculated for each PV-CTC cutoff. In order to avoid data overfitting, these DOR 475 
values were fitted into a polynomial curve, and the optimal cutoff for PV-CTC counts 476 
was selected as the one that corresponds to the maximum point of the curve.  477 
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All analysis were performed according to REMARK guideline 21, using R version 478 
3.5.122. R packages survival (v2.38)23, and survminer (v0.3)24 and survivalROC 479 
(v1.0.3)25 were applied. 480 
 481 
Lung cancer specific relapse event analysis 482 
We collected available clinical data from all 37 patients who had been reported as 483 
having experienced a DFS event (defined as the time from study enrolment until 484 
recurrence of tumour or death from any cause) in the February 2019 TRACERx data 485 
release. Clinical data was available for 35 of 37 patients, 2 patients without available 486 
data (CRUK0005 and CRUK0770) were excluded from this analysis. We defined a 487 
lung cancer specific relapse event as histological or imaging confirmed NSCLC 488 
relapse. Nine of 37 patients who experienced a DFS event died without evidence of 489 
a lung cancer specific relapse event (details in Supplementary Table 3). These 490 
patients were either censored at the point of last computed tomography (CT) scan 491 
imaging prior to death showing the absence of metastatic disease (CRUK0056, 492 
CRUK0431, CRUK0416, CRUK0260, CRUK0017, CRUK0301) or in the event of 493 
immediate post-operative death (death within 30 days of surgery), at the point of 494 
death (CRUK0196, CRUK0223, CRUK0681). Four of 37 patients experienced 495 
metastatic disease unrelated to their original lung primary (CRUK0768, 496 
CRUK0068,CRUK0759, CRUK0085) and were censored at the point of last CT 497 
imaging prior to death showing absence of metastatic NSCLC. These cases were 498 
classified as second primary malignancies based on consensus imaging, histological 499 
and clinical agreement. For 1 of 37 patients there was high clinical suspicion of a 500 
second malignancy based on CT imaging but due to lack of investigation this was 501 
not conclusively determined, therefore this patient was excluded from the analysis 502 
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(CRUK0073). Initial site of clinical relapse was defined as extracranial if no brain 503 
metastasis were clinically confirmed within 60 days of clinical relapse or intracranial if 504 
a patient presented with brain metastases within 60 days of clinical relapse. 505 
 506 
Blood collection 507 
A blood sample (10mL) was taken intra-operatively from the cancer-draining 508 
pulmonary vein prior to vessel ligation and tumour resection for each patient. A 509 
second sample was taken from the peripheral vein of patients recruited in 510 
Manchester. Blood samples were stored at room temperature for up to 96 hours in 511 
CellSave vacutainers prior to analysis.  512 
 513 
CTC enrichment enumeration and single cell isolation  514 
Blood samples were processed using the CellSearch system (Menarini), according 515 
to the manufacturer's instructions. Epithelial CTCs (via EpCAM dependent capture) 516 
were classified and counted based on an intact DAPI stained nucleus and positive 517 
immunofluorescent staining for pan-cytokeratins (CK) and negative staining for the 518 
WBC marker CD45. Following CellSearch® enrichment, single cells were isolated 519 
using the DEPArray™ system (Menarini) according to the manufacturer's 520 
instructions. Images of isolated PV-CTCs were manually inspected by two 521 
independent operators to confirm that the following morphological criteria were met: 522 
(1) cells were unambiguous positive for cytokeratin, (2) had an intact nucleus and (3) 523 
were clear of contaminating WBCs. Cells that failed to meet any of the three criteria 524 
were considered “ambiguous” and excluded from all downstream analysis. 525 
 526 
Whole genome amplification    527 
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Whole genome amplification (WGA) was performed using the Ampli1 WGA kit 528 
(Menarini) according to the manufacturer's instructions.  The efficacy of WGA was 529 
then evaluated by a multiplex quality control PCR (Ampli1 QC kit, Menarini) as 530 
previously described 26 followed by visualization of PCR bands on a 1.5% (w/v) 531 
agarose gel. This quality control step allowed us to establish a Genome Integrity 532 
Index (GII) of 0–4 for each sample and single cells with GII≥2 were considered with 533 
good quality DNA and eligible for subsequent downstream analysis. 534 
 535 
Circulating cell-free DNA and tumour samples preparation  536 
Plasma from CellSave blood samples was separated for cfDNA extraction as 537 
previously described27. Genomic DNA from primary and relapse tumours was 538 
isolated as described in Jamal-Hanjani et al12, sheared and quantified along with 539 
cfDNA and germline samples using the TaqMan RNase P Detection Kit (Life 540 
Technologies) as per manufacturer’s instructions.  541 
 542 
DNA library preparation, targeted enrichment and next-generation sequencing 543 
DNA libraries for PV-CTCs and WBCs were prepared using NEBNext Ultra DNA 544 
Library Prep Kit for Illumina (New England BioLabs) with 50 ng of DNA added per 545 
library preparation. DNA libraries for cfDNA, tumour DNA and germline were 546 
prepared using NEBNext Ultra II End Repair/dA-Tailing Module (New England 547 
BioLabs) and KAPA Hyper Library Prep Kit (KAPA Biosystems) using an input of up 548 
to 25 ng DNA. Each library was quantified (KAPA library quantification kit, KAPA 549 
Biosystems) and equimolar amounts were pooled and shallow-depth whole genome 550 
sequencing was performed on Illumina MiSeq or NextSeq 500 desktop sequencers 551 
(paired end, 300 cycles).  552 
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PV-CTC and WBC Libraries from patient CRUK0242 were additionally subjected to 553 
targeted exome enrichment using SureSelect Human All Exon V6 (Agilent) and 554 
Whole Exome Sequencing (WES) was performed on Illumina NextSeq 500 desktop 555 
sequencer for the detection of somatic mutations (paired end, 300 cycles). WES of 556 
corresponding excised primary tumour regions was performed as previously 557 
described3. For patient CRUK0242, libraries of cfDNA, isolated at surgery and at 558 
relapse, were enriched for a panel of 520 (SureSelectXT Custom, Agilent) pre-559 
identified mutations and sequenced as above.  560 
Sequence alignment and data processing 561 
After trimming of sequencing adapters, the single cell sequencing reads (fastq 562 
format) were aligned to human genome assembly 19 (hg19), using the Burrows-563 
Wheeler Aligner (BWA) mem (v0.7.13) algorithm28 to generate SAM files. SAMtools 564 
(v0.1.19) was used to convert the SAM files to BAM files, to remove reads with low 565 
mapping quality (MQ < 10) and to merge files from the same cell. Picard tools 566 
(v1.96) was used to sort the BAM files by chromosome coordinates and to remove 567 
PCR duplicates. The BAM files were converted to BED files using Bedtools29. A 568 
combination of Picard tools, Bedtools and FastQC30 was used to generate quality 569 
control metrics. 570 
 571 
WGA Capture-rate 572 
To establish the capture-rate of the WGA process, we used targeted sequencing 573 
data (described above) for comparisons of the germline (GL), WGA germline (WGA-574 
GL) and individual single cells (including WBC controls) following WGA. A list of 575 
heterozygous single nucleotide polymorphisms (SNPs) detected within the targeted 576 
regions of the germline sample was generated using Mutect (v1.1.7)31.  SAMtools 577 
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mpileup was then used to check which of these SNPs were detected in each WGA 578 
sample, requiring a minimum of ten reads to call the SNPs (average read depth in 579 
successfully amplified regions is ~230 reads) and a Variant Allele Frequency (VAF) 580 
of 0.2-0.8 to consider it to still be heterozygous. The WGA-GL sample shows a 581 
complete locus drop-out of 18% due to lack of amplification in the WGA process. Of 582 
the 113 heterozygous SNPs that are present in the WGA-GL, 51 and 54 are also 583 
called as heterozygous in the two WBC controls. In addition 16 loci became 584 
homozygous for the SNP in each cell, and 12 and 13 loci becoming homozygous for 585 
the reference allele due to allele drop out (Supplementary Table 6). This gives an 586 
estimate for the allele capture-rate of 58-61% of the 113 WGA-GL SNPs due to the 587 
single cell sequencing. 588 
 589 
Copy Number Analysis  590 
Illumina whole-genome data for PV-CTCs, WBCs and tumour samples were aligned 591 
to the human genome using BWA. For CNA analysis we only analysed samples with 592 
a minimum of 2 million reads (after duplicate removal). Copy number alterations 593 
were identified using the R Bioconductor package HMMcopy (v1.18)32 with the 594 
genome divided into 1 Mb windows. Reads in each window were normalized by GC-595 
content and mappability, and a Hidden Markov Model-based approach was used to 596 
segment the data into regions of similar copy-number profile and to predict a CNA 597 
event for each segment.  598 
 599 
Somatic Mutation analysis from whole exome and targeted sequencing data  600 
For the tumour WES, high-confidence variant calls from tumour were obtained as 601 
previously described3, using a combination of Varscan2 and MuTect. 602 
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MuTect (v1.1.7)31 was used to detect SNVs utilising annotation files contained in 603 
GATK bundle. All variants called by MuTect were filtered according to the filter 604 
parameter ‘PASS’ in the judgement column. All variants were annotated using 605 
ANNOVAR33. Only variants with at least 20 reads were considered for further 606 
filtering. 607 
To generate a high-confidence set of variant calls from PV-CTCs, the following filters 608 
were applied: 609 
1. Using the annotations as provided by ANNOVAR, all variants that were 610 
present  in either 1000g or the Exac03 databases are removed. 611 
2. A blacklist filter, relating to the genomic location of the variant, was applied. 612 
The blacklisted genomic regions were obtained from UCSC Genome Table Browser 613 
and include regions excluded from the Encode project (both DAC and Duke list), 614 
simple repeats, segmental duplications and microsatellite regions. 615 
3. Variants with VAF < 0.2 are removed. 616 
4. Variants had to be either present in the Tumour tissue (Primary or Relapse) or 617 
in at least one other single PV-CTC.  618 
5. Lastly, if any variant is called in any of the WBC controls, then those were 619 
filtered out.  620 
Supplementary Tables 9-10 and Supplementary Table 11 contain the information 621 
relative to coverage and VAF for each mutation detected in the primary tumour and 622 
single cells by WES and targeted deep sequencing respectively.  623 
 624 
For the two WBC controls from patient CRUK0242, the first three filtering steps give 625 
134 and 253 variants, none of which are shared with the tumour or any other single 626 
cells while the non-matching three CECs have 254, 260 and 307 private SNVs. The 627 
 27 
rate of false positives due to sequencing artefacts, with a range of 134-1960 variants  628 
seen in white blood samples from two other patients (see Supplementary Table 12) 629 
has very little overlap between them. The requirement that a mutation must be 630 
present in two or more samples (whether tumour or single cell) therefore eliminates 631 
the vast majority of false positives as a very conservative proceedure. 632 
 633 
Regions containing mutations detected in the primary tumour or metastasis which 634 
were not covered in at least 1 of the three PV-CTC samples were removed for the 635 
calculation of overlaps, although they are shown in the  Extended Data Fig.5.  636 
 637 
All somatic variants detected in PV-CTCs were analysed by using cancer genome 638 
interpreter platform34 to interpret whether the variants detected had potential as 639 
drivers in NSCLC as well as in other solid cancers.  640 
 641 
Phylogenetic Analysis 642 
Phylogenetic analysis was performed as previously described3. In brief, using the 643 
pigeon-hole principle (if the average cancer cell fraction of two subclones sums to 644 
more than 1, the smaller subclone must be nested within the larger) as well as the 645 
crossing rule (if the cancer cell fraction of subclone A and subclone B sums to less 646 
than 1 and the cancer cell fraction of subclone A exceeds that of subclone B in one 647 
region but the inverse is true in another region, subclone A and B must exist on 648 
separate branches of the evolutionary tree), the evolutionary relationships between 649 
subclones was determined and a phylogenetic tree inferred.   650 
  651 
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Data Availability Statement 652 
The majority of data generated or analysed during this study are included in this 653 
published article. The sequencing data are available through the Cancer Research 654 
UK & University College London Cancer Trials Centre for non-commercial research 655 
purposes and access will be granted upon review of a project proposal that will be 656 
evaluated by a TRACERx data access committee and entering into an appropriate 657 
data access agreement subject to any applicable ethical approvals. 658 
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